Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) EBIT (2020 - 2025)

Historic EBIT for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $6.7 million.

  • Xeris Biopharma Holdings' EBIT rose 15220.66% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year increase of 12170.22%. This contributed to the annual value of -$33.6 million for FY2024, which is 2354.92% up from last year.
  • According to the latest figures from Q3 2025, Xeris Biopharma Holdings' EBIT is $6.7 million, which was up 15220.66% from $4.5 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' EBIT registered a high of $6.7 million during Q3 2025, and its lowest value of -$48.3 million during Q4 2021.
  • Moreover, its 5-year median value for EBIT was -$14.2 million (2024), whereas its average is -$14.0 million.
  • As far as peak fluctuations go, Xeris Biopharma Holdings' EBIT crashed by 16242.62% in 2024, and later skyrocketed by 15474.53% in 2025.
  • Quarter analysis of 5 years shows Xeris Biopharma Holdings' EBIT stood at -$48.3 million in 2021, then skyrocketed by 68.57% to -$15.2 million in 2022, then surged by 35.13% to -$9.8 million in 2023, then surged by 117.06% to $1.7 million in 2024, then skyrocketed by 300.89% to $6.7 million in 2025.
  • Its EBIT stands at $6.7 million for Q3 2025, versus $4.5 million for Q2 2025 and -$3.1 million for Q1 2025.